General Information of Drug (ID: DM48F3D)

Drug Name
HU210 Drug Info
Synonyms
HU-210; HU 210; 112830-95-2; HU210; UNII-191042422P; CHEMBL307696; (-)-HU-210; 191042422P; (6aR-trans-3-(1, 1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; GTPL731; SCHEMBL1517460; DTXSID30150188; HU-210, solid (air sensitive); ZINC2572463; PDSP2_000201; BDBM50067499; MFCD01074786; AKOS024458716; (6aR,10aR)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol; 924H455
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9821569
CAS Number
CAS 112830-95-2
TTD Drug ID
DM48F3D

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [3]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [4]
Orlistat DMRJSP8 Obesity 5B81 Approved [5]
SR141716A DMCO5JZ Obesity 5B81 Approved [6]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [7]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [8]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [9]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [10]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [11]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 731).
2 The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004 Apr;113(8):1202-9.
3 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
4 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
5 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
6 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
7 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
8 Clinical pipeline report, company report or official report of AstraZeneca (2009).
9 Company report (Gwpharm)
10 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
11 Clinical pipeline report, company report or official report of Bird Rock Bio.
12 Clinical pipeline report, company report or official report of Affimed Therapeutics.